In a clinical trial of 442 patients taking BAVENCIO with INLYTA versus 444 patients taking a medicine called sunitinib, researchers studied:
BAVENCIO with INLYTA is not a cure. The data represent an average of patients in the clinical trial, and not all patients may experience the same results.
Together Can Be Powerful
In a clinical trial of 442 patients taking BAVENCIO with INLYTA versus 444 patients taking a medicine called sunitinib:
BAVENCIO with INLYTA decreased the overall risk of disease progression or death by 31% compared to sunitinib (progression-free survival).
Patients taking BAVENCIO with INLYTA experienced a median PFS of 13.8 months. Median time period means that half the patients went longer than 13.8 months with no tumor growth or spread, and the other half went less than 13.8 months with no tumor growth or spread. Patients taking sunitinib experienced a median PFS of 8.4 months. That’s a 5-month increase in median PFS for patients taking BAVENCIO with INLYTA compared to patients taking sunitinib.
At the time data were collected, overall survival data were immature, which means that there was not yet enough information available to assess the impact of BAVENCIO with INLYTA compared to sunitinib on overall survival.
BAVENCIO with INLYTA reduced tumor size in twice as many patients compared to sunitinib (objective response rate).
This includes patients whose tumors shrank 30% or more and whose response to treatment lasted at least 4 weeks.
How BAVENCIO® (avelumab) and INLYTA® (axitinib) Work
BAVENCIO and INLYTA are 2 different types of medicines that work in 2 different ways.